Royalty Pharma PLC
NASDAQ:RPRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Royalty Pharma PLC
NASDAQ:RPRX
|
US |
|
WH Ireland Group PLC
LSE:WHI
|
UK |
|
G
|
Geekco Technologies Corp
XTSX:GKO
|
CA |
|
R
|
Reply SpA
SWB:REJA
|
IT |
|
Digital Brands Group Inc
NASDAQ:DBGI
|
US |
|
Vallianz Holdings Ltd
SGX:WPC
|
SG |
|
A
|
AMD Industries Ltd
NSE:AMDIND
|
IN |
|
360 Capital Group Ltd
ASX:TGP
|
AU |
|
Radian Group Inc
NYSE:RDN
|
US |
|
Galata Wind Enerji Anonim Sirket
IST:GWIND.E
|
TR |
|
F
|
Field Trip Health & Wellness Ltd
XTSX:FTHW
|
CA |
|
D
|
DSJ Keep Learning Ltd
NSE:KEEPLEARN
|
IN |
|
A
|
Atlas Air Worldwide Holdings Inc
F:W8W
|
US |
|
Alaska Energy Metals Corp
OTC:AKEMF
|
CA |
|
Grupo Nacional Provincial SAB
BMV:GNP
|
MX |
|
T
|
Tessellis SpA
MIL:TSL
|
IT |
|
D
|
D3 Energy Ltd
ASX:D3E
|
AU |
|
SeaBird Exploration PLC
OSE:SBX
|
CY |
|
Lincoln Electric Holdings Inc
NASDAQ:LECO
|
US |
Wall Street
Price Targets
RPRX Price Targets Summary
Royalty Pharma PLC
According to Wall Street analysts, the average 1-year price target for
RPRX
is 53.03 USD
with a low forecast of 46.46 USD and a high forecast of 64.05 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is RPRX's stock price target?
Price Target
53.03
USD
According to Wall Street analysts, the average 1-year price target for
RPRX
is 53.03 USD
with a low forecast of 46.46 USD and a high forecast of 64.05 USD.
What is Royalty Pharma PLC's Revenue forecast?
Projected CAGR
16%
For the last 7 years the
compound annual growth rate for
Royalty Pharma PLC's revenue is
4%.
The projected
CAGR
for the next 3 years is
16%.
What is Royalty Pharma PLC's Operating Income forecast?
Projected CAGR
25%
For the last 7 years the
compound annual growth rate for
Royalty Pharma PLC's operating income is
2%.
The projected
CAGR
for the next 3 years is
25%.
What is Royalty Pharma PLC's Net Income forecast?
Projected CAGR
67%
For the last 7 years the
compound annual growth rate for
Royalty Pharma PLC's net income is
-8%.
The projected
CAGR
for the next 3 years is
67%.
